Watch out Bris­tol My­ers, Mer­ck is right on your heels with more pos­i­tive Keytru­da da­ta to take to the FDA

Mer­ck an­nounced pos­i­tive Phase III re­sults to back yet an­oth­er in­di­ca­tion for cash cow Keytru­da — this time as a first-line esophageal can­cer treat­ment in com­bi­na­tion with chemother­a­py.

Keytru­da al­ready has the FDA OK as a sec­ond-line monother­a­py for PD-L1-pos­i­tive pa­tients with re­cur­rent lo­cal­ly ad­vanced or metasta­t­ic squa­mous cell car­ci­no­ma of the esoph­a­gus. But Mer­ck is still push­ing for first-line ap­proval as a ther­a­py for the dif­fi­cult-to-treat can­cer, and it met pri­ma­ry end­points in a Phase III tri­al.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER